Reliance Global Group, Inc. (EZRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 28, 2026, details the formation of a new investment vehicle and a related-party transaction by Reliance Global Group, Inc. The Company established LifeSci Global Group LLC ("LGG") to identify and invest in healthcare-related companies, with an initial focus on early-stage life sciences. The report covers definitive agreements executed on April 29 and April 30, 2026.
Key Financial Metrics and Transaction Details
- Investment Vehicle Structure: The Company holds approximately 51% of LGG membership interests. The remaining 49% is held by LifeSci Management Group LLC, owned by Company Chairman/CEO Ezra Beyman, Director Scott Korman, and David Turner.
- Debt Facility: A Promissory Note was established with a maximum principal amount of $2,000,000. It bears interest at 7% per annum, compounded annually. As of the closing date, $500,000 in principal was advanced.
- Initial Investment: LGG subscribed for up to 421,053 Class A units of Innervate Radiopharmaceuticals LLC at $4.75 per unit, totaling approximately $2,000,001.75.
- Liquidity and Margins: The filing does not provide consolidated revenue, profit, cash flow, or margin data for the Company.
Material Changes and Related-Party Transactions
The filing discloses significant related-party transactions involving Company insiders:
- Related Parties: Ezra Beyman (Chairman/CEO) and Scott Korman (Director) hold indirect equity interests in LGG through Management Group. Additionally, Mr. Korman serves as CEO and a board member of Innervate, the recipient of the investment.
- Board Approval: Transactions were reviewed and approved by independent and disinterested Board members. Mr. Beyman and Mr. Korman recused themselves from voting.
- Investment Terms: LGG is entitled to a one-time priority distribution of $4.75 per unit from Innervate proceeds (e.g., Priority Review Voucher sale) and warrants to purchase additional units (cap of 210,526 warrants) at a $4.75 strike price, expiring October 31, 2029.
Corporate Governance Changes
Effective April 28, 2026, the Board restructured its standing committees to ensure independence following the related-party transactions:
- Audit Committee: Scott Korman removed as Chairman and member. Ben Fruchtzweig appointed Chairman; Alex Blumenfrucht appointed member.
- Compensation Committee: Scott Korman removed as member. Ben Fruchtzweig removed as Chairman. Alex Blumenfrucht appointed Chairman and member.
- Nominating Committee: Scott Korman removed as member. Alex Blumenfrucht appointed member.
- Outcome: All three committees now consist solely of independent directors.
Investor Verification Checklist
- Verify the full text of the Promissory Note (Exhibit 10.1) for default triggers and repayment terms beyond the summary.
- Review the Unit Subscription Agreement (Exhibit 10.2) and Side Letter (Exhibit 10.3) to understand the specific conditions for the priority distribution and warrant exercise.
- Confirm the financial health and development stage of Innervate Radiopharmaceuticals LLC, as the investment targets an early-stage company.
- Monitor future filings for additional advances under the $2,000,000 Promissory Note, as the Company may make further discretionary advances.
- Assess the impact of the new investment vehicle on the Company's consolidated financial statements in upcoming periodic reports.